Clinical significance of C-reactive protein/platelet ratio from diagnosis to allogeneic hematopoietic stem cell transplantation in acute myeloid leukemia
Annals of Hematology · 2025
DOI: 10.1007/s00277-025-06470-3 ↗Kurz gefasst
Multizentrische Studie in der Zeitschrift Annals of Hematology, 2025. Verfasst von Akihiko Izumi und 13 weiteren Autor:innen. Beteiligte Einrichtung: Department of Hematology, Kanagawa Cancer Center, Yokohama, Japan. Hauptthemen laut MEDLINE: Leukemia, Myeloid, Acute, Hematopoietic Stem Cell Transplantation, C-Reactive Protein, Blood Platelets. Die Arbeit nennt 28 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY-NC-ND 4.0).
Abstract (Originalsprache)
Previous studies have shown that C-reactive protein/platelet ratio (CPR) before allogeneic hematopoietic stem cell transplantation (HSCT) is a predictor of survival in patients with hematological malignancies. This multicenter retrospective study aimed to evaluate the clinical significance of CPR from diagnosis to HSCT in patients with acute myeloid leukemia (AML) who underwent HSCT. This cohort included patients with AML who underwent their first HSCT between 2016 and 2021. CPR was evaluated at three time points: at diagnosis, after initial therapy, and pre-HSCT. The cut-off value for CPR was set at 0.05 based on previous studies. In total, 196 patients with a median age of 50 years (range: 15-72). High CPR was associated with the myeloblast ratio in the bone marrow at three points and was associated with high transfusion volume and poor performance status at HSCT. Overall survival (OS) at 2 years according to CPR at diagnosis, after initial therapy, and pre-HSCT (low vs. high) was 67.9% vs. 65.6% (P = 0.477), 72.6% vs. 54.8% (P = 0.022), and 73.1% vs. 49.7% (P < 0.001), and non-relapse mortality (NRM) was 15.8% vs. 19.0% (P = 0.557), 13.8% vs. 21.5% (P = 0.201), and 13.0% vs. 27.6% (P = 0.006), respectively. No significant differences were observed in the relapse rates. In multivariate analysis, the high CPR group pre-HSCT was associated with poor OS (HR = 1.86, 95%CI:1.13-3.07, P = 0.015) and higher NRM (HR = 2.52, 95%CI:1.26-5.04, P = 0.009). Pre-HSCT CPR was associated with post-HSCT OS and NRM. CPR is considered a marker that reflects the disease status and patient condition, suggesting the significance of CPR monitoring.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- Department of Hematology, Kanagawa Cancer Center, Yokohama, Japan.
- Department of Hematology, Kanagawa Cancer Center, Yokohama, Japan. tachibana.tak.kt@yokohama-cu.ac.jp.
- Department of Stem Cell and Immune Regulation, Yokohama City University Graduate School of Medicine, Yokohama, Japan.
- Department of Hematology, Yokohama City University Medical Center, Yokohama, Japan.
Zitieren
APA
Izumi, A., Tachibana, T., Nukui, J., Miyazaki, T., Hirose, N., Ohashi, T., Tanaka, M., Katsuki, K., Suzuki, T., Nakajima, Y., Matsumoto, K., Fujisawa, S., Tanaka, M., & Nakajima, H. (2025). Clinical significance of C-reactive protein/platelet ratio from diagnosis to allogeneic hematopoietic stem cell transplantation in acute myeloid leukemia. Annals of Hematology. https://doi.org/10.1007/s00277-025-06470-3
Vancouver
Izumi A, Tachibana T, Nukui J, Miyazaki T, Hirose N, Ohashi T, et al. Clinical significance of C-reactive protein/platelet ratio from diagnosis to allogeneic hematopoietic stem cell transplantation in acute myeloid leukemia. Annals of Hematology. 2025. doi:10.1007/s00277-025-06470-3
BibTeX
@article{Izumi2025,
author = {Izumi, Akihiko and Tachibana, Takayoshi and Nukui, Jun and Miyazaki, Takuya and Hirose, Natsuki and Ohashi, Takuma and Tanaka, Marika and Katsuki, Kengo and Suzuki, Taisei and Nakajima, Yuki and Matsumoto, Kenji and Fujisawa, Shin and Tanaka, Masatsugu and Nakajima, Hideaki},
title = {Clinical significance of C-reactive protein/platelet ratio from diagnosis to allogeneic hematopoietic stem cell transplantation in acute myeloid leukemia},
journal = {Annals of Hematology},
year = {2025},
doi = {10.1007/s00277-025-06470-3}
}
EUVIMED